Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical Rheumatology
Literature
1.
Sapkota HR, Nune A (2022) Long COVID from rheumatology perspective - a narrative review. Clin Rheumatol 41:337–348CrossRef
2.
3.
Ramos-Casals M, Brito-Zerón P, Mariette X (2021) Systemic and organ-specific immune-related manifestations of COVID-19. Nat Rev Rheumatol 17:315–332CrossRef
4.
Bastard P, Rosen LB, Zhang Q et al (2020) Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science 370:eabd4585CrossRef
5.
Zhang Q, Bastard P, Liu Z et al (2020) Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science 370:eabd4570CrossRef
6.
Jog NR, Young KA, Munroe ME et al (2019) Association of Epstein-Barr virus serological reactivation with transitioning to systemic lupus erythematosus in at risk-individuals. Ann Rheum Dis 78:1235–1241CrossRef
7.
Marino Gammazza A, Légaré S, Lo Bosco G et al (2020) Human molecular chaperons share with SARS-CoV-2 antigenic epitopes potentially capable of eliciting autoimmunity against endothelial cells: possible role of molecular mimicry in COVID-19. Cell Stress Chaperons 25:737–741CrossRef
8.
Metadata
Title
Long COVID from rheumatology perspective: a simple mimicker or promoter of autoimmunity?
Authors
Alexandros A. Drosos
Eleftherios Pelechas
Paraskevi V. Voulgari
Publication date
01-03-2022
Publisher
Springer International Publishing
Published in
Clinical Rheumatology / Issue 3/2022
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-022-06092-4

Other articles of this Issue 3/2022

Clinical Rheumatology 3/2022 Go to the issue

Original Article

Functional capacity vs side effects: treatment attributes to consider when individualising treatment for patients with rheumatoid arthritis

Original Article

Fluorine-18 labeled fluorodeoxyglucose positron emission tomography/computed tomography used in diagnosing connective tissue diseases in fever of unknown origin/inflammatory of unknown origin patients

Correction

Correction to: Effect of JAK inhibitors on high- and low-density lipoprotein in patients with rheumatoid arthritis: a systematic review and network meta-analysis

Brief Report

Autologous ATG-free hematopoietic stem cell transplantation for refractory autoimmune rheumatic diseases: a Latin American cohort

Letter to the Editor

Mean platelet volume may not have a predictive value for renal involvement in Henoch-Schönlein purpura secondary to Mycoplasma pneumoniae infection

Original Article

Comparison study of bead-based and line-blot multiplex ANA immunoassays in the diagnosis of systemic autoimmune rheumatic diseases
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits